跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 4,717 条关于
“SCN2A Foundation”
全部
4,717
临床试验
160
药物
68
机构
474
资讯
4,015
7个月前
Unravel Biosciences Partners with SCN2A Foundation to Target Loss-of-Function Mutations in Autism and Epilepsy
去年
FamilieSCN2A and Cellectricon Join Forces to Advance Drug Development for Autism and Epilepsy-Linked SCN2A Gene
2年前
Relutrigine Shows Promise in Reducing Seizures in SCN2A/SCN8A-DEE Phase 2 Trial
2个月前
Personalized ASO Gene Therapy Dramatically Reduces Seizures and Restores Walking in Children with SCN2A-Related Epilepsy
上个月
Allele-Selective ASO Therapy Enables Teen with Rare SCN2A Epilepsy to Walk for the First Time
去年
Praxis Precision Medicines Presents Promising Epilepsy Pipeline Updates at AES 2024
9个月前
Praxis Precision Medicines to Showcase Epilepsy Pipeline at AES 2025 with Full RADIANT Study Results
9个月前
Praxis Precision Medicines Reports Positive EMBOLD Study Results for Relutrigine in Rare Epileptic Encephalopathies
去年
FDA Grants Rare Pediatric Disease Designation to Praxis' Relutrigine for Dravet Syndrome
去年
Praxis Precision Medicines Announces Pipeline Advancements and Financial Results for Q3 2024
第 1 页,共 402 页
上一页
下一页